Long-acting bronchodilators may be combined with inhaled glucocorticosteroids, but the current GOLD guidelines call for minimizing the use of inhaled corticosteroids in COPD treatment. Doctors may ...

A further step in the process of developing better service and standards of care for patients with COPD The full version of the new NICE guidelines on the management of chronic obstructive pulmonary ...

The US Food and Drug Administration (FDA) has approved mepolizumab as a maintenance treatment for chronic obstructive ...

This document provides a systematic, evidence-based review of the pulmonary rehabilitation literature that updates the 1997 guidelines published by the American College of Chest Physicians (ACCP ...

Long-term oxygen therapy (LTOT) is linked to reduced exacerbations and hospitalizations among patients with chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), and pulmonary ...

19] ATS/ERS: Joint American Thoracic Society/European Respiratory Society COPD management guidelines; COPDX: Australian and New Zealand COPD guidelines; GOLD: Global Initiative for Obstructive ...

All guidelines state that COPD is indeed a treatable disease, so that’s the word we want to get across. Dr. Yamo Deniz Unfortunately, our healthcare systems are currently not recognizing unmet ...

The FDA approved mepolizumab (Nucala) for adults with inadequately controlled chronic obstructive pulmonary disease (COPD), drugmaker GSK announced on Thursday. Labeling for the interleukin-5 (IL ...

The American Society of Hematology (ASH) and the International Society on Thrombosis and Hemostasis (ISTH) released new and ...

Perspective from Mike Hess, MPH, RRT, RPFT The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, according to a GSK press ...

London: GSK plc has received approval from the US Food and Drug Administration (FDA) for Nucala (mepolizumab) as an add-on ...

May 23, 2025 -- The FDA has approved the asthma drug Nucala for adults with chronic obstructive pulmonary disease (COPD). It is the second biologic therapy approved for the condition, following ...